SALIM VIRANI to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications SALIM VIRANI has written about Randomized Controlled Trials as Topic.
Connection Strength
2.586
-
The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials. Cardiovasc Drugs Ther. 2024 Dec; 38(6):1415-1420.
Score: 0.610
-
Major Randomized Clinical Trials in Cardiovascular Disease Prevention Presented at the 2019 American College of Cardiology Annual Scientific Session. Curr Atheroscler Rep. 2019 05 24; 21(8):31.
Score: 0.462
-
Aspirin for the Primary Prevention of Cardiovascular Disease: In Need of Clarity. Curr Atheroscler Rep. 2016 Jan; 18(1):4.
Score: 0.365
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American College of Cardiology Conference. Curr Atheroscler Rep. 2023 06; 25(6):309-321.
Score: 0.151
-
What is really new in triglyceride guidelines? Curr Opin Endocrinol Diabetes Obes. 2023 04 01; 30(2):73-80.
Score: 0.149
-
Highlights of Cardiovascular Disease Studies Presented at the 2021 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2022 01; 24(1):61-72.
Score: 0.139
-
Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session. Curr Atheroscler Rep. 2020 06 18; 22(8):32.
Score: 0.124
-
Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials. Curr Atheroscler Rep. 2019 01 10; 21(1):1.
Score: 0.113
-
Evaluating Periodontal Treatment to Prevent Cardiovascular Disease: Challenges and Possible Solutions. Curr Atheroscler Rep. 2017 Jan; 19(1):4.
Score: 0.098
-
Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria. Am J Med. 2015 Nov; 128(11):1253-6.
Score: 0.088
-
Impact of colchicine on pericardial inflammatory syndromes--an analysis of randomized clinical trials. Int J Cardiol. 2012 Nov 01; 161(1):59-62.
Score: 0.072
-
Update on therapies targeting HDL: the mystery continues. Curr Opin Lipidol. 2011 Dec; 22(6):514-6.
Score: 0.069
-
Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. Methodist Debakey Cardiovasc J. 2022; 18(5):40-53.
Score: 0.037
-
Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Special Report From the American Heart Association and American College of Cardiology. Circulation. 2019 06 18; 139(25):e1162-e1177.
Score: 0.028
-
Use of cardiopulmonary pump support during coronary artery bypass grafting in the high-risk: a meta-analysis. Ir J Med Sci. 2018 May; 187(2):369-377.
Score: 0.026
-
Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials. Cardiovasc Drugs Ther. 2016 Apr; 30(2):189-98.
Score: 0.023
-
Clinical outcomes of percutaneous interventions in saphenous vein grafts using drug-eluting stents compared to bare-metal stents: a comprehensive meta-analysisof all randomized clinical trials. Clin Cardiol. 2012 May; 35(5):291-6.
Score: 0.018
-
Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2009 Dec 15; 54(25):2388-95.
Score: 0.015